62 results about "Microbial transglutaminase" patented technology

The present invention provides a neutral metalloprotease from actinomycetes which selectively cleaves a pro-structure part of a microbial protransglutaminase and a gene encoding said neutral metalloprotease. An active microbial transglutaminase having the pro-structure part cleaved can be obtained by culturing a microorganism into which a gene encoding the neutral metalloprotease from actinomycetes according to the present invention has been introduced, where by producing the neutral metalloprotease from actinomycetes, and reacting it on a microbial protransglutaminase.

The invention provides glutamine transaminase with improved enzymatic activity, wherein the amino acid sequence is shown as SEQ ID NO.1. According to the invention, amino acid at the N end of MTG (Microbial Transglutaminase) maturase is subjected to deficiency and saturation mutation by taking the efficient expression of MTG in colibacillus as an improvement platform, and a mutant strain with good enzymatic property is obtained. The enzyme activity is improved by 1.85 times, and the thermal stability is improved by 2.7 times. The modified enzyme is more suitable for industrial applications, the production cost can be lowered, and the production efficiency can be improved.

The invention discloses a rapid hemostatic product for clinical operation wounds, as well as a preparation method and application of the rapid hemostatic product. The rapid hemostatic product comprises a matrix containing a microbial transglutaminase (mT6), wherein the amino acid sequence of the transglutaminase is the protein sequence coded by the gene shown in SEQ ID NO.: 3, or the protein sequence shown in SEQ ID NO.: 4. Specifically, the rapid hemostatic product is selected from a hemostatic, a hemostatic device, a hemostatic first-aid kit or a common hemostatic product; the matrix adopts a fluid or semisolid form, which can be absorbed by a human body, or a plastic gel or colloid form. The rapid hemostatic product contains the microbial transglutaminase and gelatin. The rapid hemostatic product has the advantages of rapid hemostatic property, convenience for use, prevention on organ adhesion, promotion on wound healing, low toxic and side effects, complete absorption and the like. The rapid hemostatic product can be used as a medical hemostatic material or product for clinical operation wounds, can stop bleeding rapidly, prevents organ adhesion, is easy to absorb, has little possibility of spreading diseases, and is low in cost.

The present invention provides novel peptide sequences for use in microbial transgluatminase-mediated, in particular mTG2-mediated bioconjugations, in particular for the manufacture of antibody-drug-conjugates. Further disclosed are bioconjugation methods employing mTG2 and the novel peptide sequence motifs of the invention. The present invention further provides proteins comprising the novel sequence motifs of the invention as well as polynucleotides encoding the same.